Antimüllerian Hormone to Determine Polycystic Ovarian Morphology: The APHRODITE Study
September 2021
in “
Fertility and Sterility
”
Studysummary This study found that the Elecsys AMH Plus immunoassay with a cutoff of 3.2 ng/mL is effective for diagnosing polycystic ovarian morphology, showing high sensitivity and specificity across different PCOS phenotypes.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The APHRODITE study, a retrospective, multicenter, case-control study involving 2,014 participants, aimed to determine a cutoff for the Elecsys AMH Plus immunoassay to identify polycystic ovarian morphology (PCOM), a criterion for polycystic ovary syndrome (PCOS). The study found that a serum Antimüllerian hormone (AMH) cutoff of 3.2 ng/mL resulted in a sensitivity of 88.6% and specificity of 84.6% for PCOM diagnosis, with similar results across PCOS phenotypes A–D. The study concluded that the Elecsys AMH Plus immunoassay is a robust method for identifying PCOM to aid in PCOS diagnosis. The study also found that body mass index (BMI) and race had no significant effect on case-control status. The findings are generalizable to European women aged 25–45 years with symptoms suggestive of PCOS.
